eShowcase: Data JumpStart
Data JumpStart helps companies deploy standardization and conversion solutions
Data JumpStart helps companies deploy standardization and conversion solutions
Octagon Research Solutions, Inc.'s (Wayne, PA) Data JumpStart assists companies in establishing data standards across their organization, as well as their outsourcing partners. Data JumpStart is an SDTM and CDISC compliant collection of documents, libraries, and templates.
It includes Case Report Form Library, a collection of 12 standard case report forms that leverage CDISC SDTM Nomenclature; Annotated Case Report Forms with SDTM variable names; Variable Names Library, which details variable names that can be used within each dataset categorized by dataset; CDISC SDTM compatible laboratory specifications for central lab vendors; Standard Query Library, which consists of approximately 50 standardized queries to provide consistent quality data; and Comprehensive Data Management Plan template, which includes 60 pages of expert guidance for the development of a data management plan.
Octagon Research Solutions, Inc., (610) 535-6500, www.octagonresearch.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
